SAB Biotherapeutics, Inc. (NASDAQ:SABSW – Get Free Report) was the target of a significant increase in short interest during the month of June. As of June 15th, there was short interest totaling 6,872 shares, an increase of 117.6% from the May 31st total of 3,158 shares. Based on an average daily volume of 38,353 shares, the days-to-cover ratio is presently 0.2 days.
SAB Biotherapeutics Stock Down 0.7%
Shares of SABSW stock opened at $0.01 on Tuesday. SAB Biotherapeutics has a 52-week low of $0.01 and a 52-week high of $0.18. The company has a 50-day simple moving average of $0.02 and a two-hundred day simple moving average of $0.03.
SAB Biotherapeutics Company Profile
SAB Biotherapeutics, Inc is a clinical-stage biopharmaceutical company specializing in the development of fully human polyclonal antibody therapeutics. The company’s core technology, known as the Transchromosomic (Tc) Bovine platform, leverages genetically engineered cattle to produce large volumes of human antibodies in response to targeted antigens. These antibodies are designed to treat a range of infectious diseases and immunological disorders, offering a complementary approach to monoclonal antibodies and traditional vaccines.
The company’s lead programs focus on combating high-priority pathogens, including emerging coronaviruses and other viral threats.
Recommended Stories
- Five stocks we like better than SAB Biotherapeutics
- The AI Boom Has a Second Act—And It’s Playing Out in Optics
- Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback?
- 5 Tech Stocks to Buy on the July Pullback
- Is OpenAI’s IPO Delay a Warning for AI Investors?
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
